MARKET

CYCC

CYCC

Cyclacel Pharma
NASDAQ
1.380
-0.080
-5.48%
After Hours: 1.350 -0.03 -2.17% 19:26 10/03 EDT
OPEN
1.490
PREV CLOSE
1.460
HIGH
1.490
LOW
1.320
VOLUME
95.20K
TURNOVER
0
52 WEEK HIGH
5.85
52 WEEK LOW
1.010
MARKET CAP
17.30M
P/E (TTM)
-0.7093
1D
5D
1M
3M
1Y
5Y
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Benzinga · 08/19 07:54
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Benzinga · 08/18 16:54
Cyclacel stock rises 16% as net loss narrows, income grows
Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose <font ...
Seekingalpha · 08/11 16:41
--Roth Capital Adjusts Cyclacel Pharmaceuticals Price Target to $16 From $24, Maintains Buy Rating
--Roth Capital Adjusts Cyclacel Pharmaceuticals Price Target to $16 From $24, Maintains Buy Rating
MT Newswires · 08/11 11:43
Cyclacel Pharmaceuticals GAAP EPS of -$0.46 beats by $0.08, revenue of $0M
Cyclacel Pharmaceuticals press release (<span...
Seekingalpha · 08/10 21:53
Cyclacel Pharmaceuticals Q2 2022 Earnings Preview
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is scheduled to an...
Seekingalpha · 08/09 21:35
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce sec...
GlobeNewswire · 08/03 13:15
1Life, Tabula Rasa top healthcare gainers; LumiraDx, Verve lead losers' pack
Gainers: 1Life Healthcare ONEM +67%. Tabula Rasa HealthCare (TR...
Seekingalpha · 07/21 14:05
More
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.